US Revenue
$233M
+8% YoY
Quarterly US generics revenue, driven by respiratory and lanreotide market share gains.
CIPLA
Healthcare
30 Oct 2025
Cipla Ltd — Q2 FY26
Cipla delivered an all-time high quarterly revenue of INR 7,589 crore (+8% YoY) with a robust EBITDA margin of 25%, driven by broad-based growth across One India, US Generics, One Africa, and EMEU.
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Cipla delivered an all-time high quarterly revenue of INR 7,589 crore (+8% YoY) with a robust EBITDA margin of 25%, driven by broad-based growth across One India, US Generics, One Africa, and EMEU. The US business contributed $233 million in revenue, with Cipla becoming the #1 player in the albuterol MDI market (22% share). The India branded business grew 7% YoY, with chronic mix improving to 61.8%. Management revised FY26 EBITDA margin guidance down to 22.75%-24% (from 23.5%-24.5%) due to higher R&D spend and declining Revlimid contribution. Key growth drivers include the tirzepatide (Yurpeak) launch in India, upcoming respiratory and peptide launches in the US, and continued momentum in EMEU. Risk: Revlimid revenue is expected to become immaterial from Q3, creating a near-term revenue gap that new launches may not fully offset.
सिप्ला ने इस तिमाही में अब तक का सबसे ज़्यादा कारोबार किया - 7,589 करोड़ रुपये (पिछले साल से 8% ज़्यादा)। कंपनी की कमाई पर मुनाफ़ा दर (EBITDA मार्जिन) 25% रही, जो अच्छा है। यह वृद्धि भारत, अमेरिका, अफ्रीका और यूरोप-मिडिल ईस्ट के कारोबार से आई। अमेरिका में 233 मिलियन डॉलर का कारोबार हुआ और सिप्ला अस्थमा की दवा (अल्ब्युटेरॉल MDI) में नंबर-1 बन गई (22% हिस्सेदारी)। भारत में ब्रांडेड दवाओं का कारोबार 7% बढ़ा, और पुरानी बीमारियों की दवाओं का हिस्सा 61.8% हो गया। कंपनी ने अगले साल के मुनाफ़े का अनुमान घटाकर 22.75%-24% कर दिया (पहले 23.5%-24.5% था), क्योंकि रिसर्च पर ज़्यादा खर्च होगा और रेवलिमिड दवा से कमाई घटेगी। आगे वृद्धि के लिए भारत में मोटापे की नई दवा (युरपीक), अमेरिका में सांस और पेप्टाइड दवाओं का लॉन्च अहम होगा। जोखिम: रेवलिमिड से कमाई तीसरी तिमाही से लगभग खत्म हो जाएगी, जिससे नई दवाएं पूरी भरपाई नहीं कर पाएंगी।
Key Numbers
Albuterol MDI Market Share
22%
+?pp YoY
Cipla became the #1 player in the US albuterol MDI market as of Sep 2025.
Lanreotide Market Share
22%
+?pp YoY
Market share as of MAT August 2025, expected to continue increasing.
India Chronic Mix
61.8%
+?pp YoY
Chronic prescription mix improved YoY, reflecting focus on high-growth therapies.
What Changed vs Last Quarter
NEW
Generic Revlimid contribution immaterial from Q3 FY26
Revlimid revenue expected to be very small in Q3 and decline further as patent expires in January.
NEW
Launch of four major respiratory assets by CY26
Includes generic Advair in Q4 2026 and three peptide assets including liraglutide.
NEW
US revenue directional target of $1B next year
Run-rate expected to reach $1B in US revenue during next fiscal year, subject to approval timelines.
UPDATED
FY26 EBITDA margin guidance revised to 22.75%-24%
Full-year EBITDA margin guidance lowered from 23.5%-24.5% due to higher R&D spend and declining Revlimid contribution.
DROPPED
US revenue target of ~$1 billion by FY27
CEO stated pipeline (including respiratory launches like generic Symbicort) should get US revenue closer to or surpass $1 billion by FY27.
DROPPED
India branded business to grow in line with IPM in next three quarters
COO expressed confidence that India branded prescription business will grow at industry rates for the remaining quarters of FY26.
DROPPED
Biosimilar launch in US expected in Q2 FY26
Company signed agreement to launch first biosimilar in US (supportive care in oncology) via partnership; own biosimilars expected by 2029-30.
NEW RISK
Execution risk on US pipeline launches
Delays in FDA approvals for key respiratory and peptide assets could impact the $1B US revenue target.
NEW RISK
Tirzepatide exclusivity and competition
Potential competition from semaglutide generics and uncertainty over exclusivity terms with Lilly could limit tirzepatide upside.
RISK GONE
Indore facility reinspection risk
Indore facility is due for US FDA reinspection within the next year; any adverse outcome could disrupt US supplies.
RISK GONE
GLP-1 market competition and execution
Management acknowledged GLP-1 market will be crowded; Cipla's strategy is still evolving and may face challenges in capturing share.
🤫 Topics management stopped discussing
Mentioned in Q2 FY25, Q3 FY25, Q4 FY25
Advair will be commercialized from the U.S. facility, with launch expected in FY26 depending on FDA prioritization.
Mentioned in Q1 FY26, Q3 FY25
Company signed agreement to launch first biosimilar in US (supportive care in oncology) via partnership; own biosimilars expected by 2029-30.
Mentioned in Q1 FY25, Q2 FY25
Goa facility received Form 483 observations; classification still awaited, which could impact Abraxane launch timeline and other approvals.
Mentioned in Q1 FY25, Q2 FY25
Supply issues at partner site will reduce Q3 lanreotide sales significantly; recovery depends on partner's production ramp-up.
Mentioned in Q2 FY25, Q3 FY25
Lanreotide supply issues impacted US revenue; management expects normalization by end of Q4, but full capacity recovery may extend into Q1 FY26.
Management Guidance
FY26 EBITDA margin guidance revised to 22.75%-24%
Full-year EBITDA margin guidance lowered from 23.5%-24.5% due to higher R&D spend and declining Revlimid contribution.
Management guidance marginsGeneric Revlimid contribution immaterial from Q3 FY26
Revlimid revenue expected to be very small in Q3 and decline further as patent expires in January.
Management guidance revenueLaunch of four major respiratory assets by CY26
Includes generic Advair in Q4 2026 and three peptide assets including liraglutide.
Management guidance growthUS revenue directional target of $1B next year
Run-rate expected to reach $1B in US revenue during next fiscal year, subject to approval timelines.
Management guidance revenueKey Risks
Revlimid revenue cliff
Generic Revlimid contribution expected to become immaterial from Q3 FY26, creating a revenue gap that new launches may not fully offset in the near term.
high · management_commentaryExecution risk on US pipeline launches
Delays in FDA approvals for key respiratory and peptide assets could impact the $1B US revenue target.
medium · analyst_questionIndia branded business growth slowdown
India branded business grew only 7% YoY, below the market, due to weak acute season and team restructuring.
medium · analyst_questionTirzepatide exclusivity and competition
Potential competition from semaglutide generics and uncertainty over exclusivity terms with Lilly could limit tirzepatide upside.
medium · analyst_questionNotable Quotes
This quarter, we delivered an all-time high quarterly revenue of INR 7,589 crores, supported by a robust EBITDA margin of 25%.
In the overall U.S. albuterol MDI market, Cipla emerged as the number one player, with our market share rising to 22%.
We are entering the obesity care segment with the launch of Yurpeak, which is tirzepatide. This is a significant milestone in our partnership with Eli Lilly.
Frequently Asked Questions
What was Cipla's revenue in Q2 FY26?
Cipla reported revenue of ₹7,589 Cr in Q2 FY26, representing a +8% change compared to the same quarter last year.
What guidance did Cipla management give for FY27?
FY26 EBITDA margin guidance revised to 22.75%-24%: Full-year EBITDA margin guidance lowered from 23.5%-24.5% due to higher R&D spend and declining Revlimid contribution. Generic Revlimid contribution immaterial from Q3 FY26: Revlimid revenue expected to be very small in Q3 and decline further as patent expires in January. Launch of four major respiratory assets by CY26: Includes generic Advair in Q4 2026 and three peptide assets including liraglutide. US revenue directional target of $1B next year: Run-rate expected to reach $1B in US revenue during next fiscal year, subject to approval timelines.
What are the key risks for Cipla in FY27?
Key risks include Revlimid revenue cliff — Generic Revlimid contribution expected to become immaterial from Q3 FY26, creating a revenue gap that new launches may not fully offset in the near term.; Execution risk on US pipeline launches — Delays in FDA approvals for key respiratory and peptide assets could impact the $1B US revenue target.; India branded business growth slowdown — India branded business grew only 7% YoY, below the market, due to weak acute season and team restructuring.; Tirzepatide exclusivity and competition — Potential competition from semaglutide generics and uncertainty over exclusivity terms with Lilly could limit tirzepatide upside..
Did Cipla meet its previous quarter's guidance?
Of 2 tracked promises, management 0 met, 0 close, 2 missed.
Where can I read the full Cipla Q2 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.